Study Duration. Recruitment: Approximately 41 months (176 weeks) Study duration per patient:
Study Duration. The Parties anticipate that the Study will be conducted during the period commencing on the Effective Date and ending approximately around . Sponsor will communicate any changes to the foregoing timeline to Site in writing.
Study Duration. For subjects, the study will consist of a Screening period for up to 30 days (but can be extended in certain circumstances, see Section 5.2.1), with randomisation at the Treatment Visit (Day 1) up to 14 days later (can be extended if UTI prevents IMP administration - see Section 5.2.3). Follow-up for each subject is planned to be 24 months (104 weeks) after the first IMP administration. However, as retreatments can occur up to Week 104, and 12 weeks of follow- up will occur following each study retreatment, the maximum planned subject participation following randomisation is 116 weeks. Each subject’s participation in the study will be considered to have ended at the time of their last study visit, including follow-up for AEs after the last IMP administration: • CCI . The study will be considered to have started when the first subject has provided signed informed consent and to have ended after the last subject has completed their last study visit.
Study Duration. Objectives of the Study: Study Endpoints: (Primary and Secondary) Study Design: Eligibility Criteria (Inclusion and Exclusion) Study Procedures: (Including pharmacokinetic (PK) sampling times) Safety Parameters/analysis: Laboratory Parameters/Analysis: Total Blood Volume: Sample Size Determination: (If applicable) Statistical Analyses: (Brief Description) Others : (As required by the specific study) 2Introduction The introduction should outline all the background information and provide a justification for conducting the study in a logical, well ordered fashion. This should include: An overview of the target indication and population for the product; A summary of pre-clinical and clinical data that is relevant to the trial, including data that justifies the use of the study medication in the target indication, with literature references; A summary of the known and potential risks and benefits, if any, to human participants; And a description of, and justification for, the route of administration, dosage, dosage regimen and treatment period(s). 3Objectives A detailed description of the objects of the study should be provided, split in to primary and secondary objectives as appropriate.
Study Duration. The study duration is approximately four years (eighteen (18) months for enrollment). There will be up to 16 weeks screening prior to randomization, including at least 3 months of drug dose stabilization (or washout) for those using antiNASH medications prior to baseline liver biopsy or prior to randomization.. The patients will undergo a 72-week treatment period followed by a 24- week post-treatment washout period.
Study Duration. Institution will make every effort to complete the study within 15 months. Institution will recruit no less than seven sites if needed to conduct the study within the 15 month period. 5. Change Orders.
Study Duration. 3.11.1 Student from Home University will study at the Host University for a minimum of one semester and vice versa.
Study Duration. For each subject, the total study duration is expected to be approximately 20 weeks as follows: Screening period: 4 weeks Treatment period: 12 weeks Follow-up period 4 weeks from last dose of study treatment
Study Duration. The Study is expected to be initiated from to .
Study Duration
